TheraCryf to hold AGM and investor presentation on July 9

Published 16/06/2025, 16:14
TheraCryf to hold AGM and investor presentation on July 9

LONDON - TheraCryf plc (AIM:TCF), a clinical stage drug development company focusing on neuropsychiatry and oncology, announced Monday that it has posted its Annual Report and Accounts for the year ended March 31, 2025, to shareholders.

The company will hold its Annual General Meeting on Wednesday, July 9, 2025, at 2:30 p.m. at the Royal Society of Medicine in London. Following the AGM, the management team will host an in-person presentation to discuss full-year results and recent progress with the company’s Orexin antagonist program.

TheraCryf develops treatments for brain disorders including addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company’s business model involves generating data to reach preclinical or clinical proof of concept before partnering its clinical programs with pharmaceutical companies for larger trials and commercialization.

The company maintains collaborations with several academic institutions, including the University of Manchester, La Sapienza University of Rome, Erasmus Medical (TASE:BLWV) Center in Rotterdam, Kings College London, and the University of Michigan.

TheraCryf is headquartered at Alderley Park in Cheshire, UK, and is listed on London’s AIM market.

The information in this article is based on a company press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.